RxDoctor Payments Data

Brian Dalton, MD

Internal Medicine · Whitman, MANPI 1609840396

Payments from drug & device makers

$584in general payments, 2019–2025

Across 31 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$114
  • Johnson & Johnson$74
  • Merck$41
  • Sanofi-aventis U.S. LLC$41
  • Novo Nordisk$37
  • Astellas Pharma US Inc$34
  • plus $242 from 12 others

What the payments were for

  • Food & beverage$584100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$584 in reported general payments places this provider in the 75th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$374,746
Medicare patients
601
Services billed
4,421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban160$150,570
TrulicityDulaglutide104$114,779
JanuviaSitagliptin Phosphate74$76,577
JardianceEmpagliflozin67$72,351
OzempicSemaglutide38$47,462
XareltoRivaroxaban35$45,278
Breo ElliptaFluticasone/Vilanterol93$41,994
MounjaroTirzepatide38$41,991
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$30,855
VascepaIcosapent Ethyl39$21,520
NexletolBempedoic Acid22$18,840
Rosuvastatin Calcium435$18,790
OxycontinOxycodone Hcl16$16,125
Atorvastatin Calcium1,047$15,305
Spiriva HandihalerTiotropium Bromide22$15,011

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$150,570160 claims
GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta$14$78,188144 claims
MerckJanuvia$41$76,57774 claims
Novo NordiskOzempic$37$47,46238 claims
Johnson & JohnsonXarelto$74$45,27835 claims
NovartisEntresto$16$13,47317 claims
Astellas Pharma US IncMyrbetriq$34$6,23615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Whitman

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →